Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2

Cancer Research

Volumn 67, Issue 24, 2007, Pages 11991-11999

  Varchetta, Stefania ^a   Gibelli, Nadia ^a   Oliviero, Barbara ^a   Nardini, Elena ^b   Gennari, Roberto ^c,d   Gatti, Giovanna ^d   Silva, Luzemira Santos ^d   Villani, Laura ^a   Tagliabue, Elda ^b   Ménard, Sylvie ^b   Costa, Alberto ^a   Fagnoni, Francesco F ^a,e  

^a Scientific Institute of Pavia   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c EUROPEAN SCHOOL OF ONCOLOGY   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e Istituto di Ricovero e Cura a Carattere Scientifico di Diritto Pubblico   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; CD69 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER PATIENT; CELL KILLING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DOWN REGULATION; DRUG MECHANISM; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LOADING DRUG DOSE; MONONUCLEAR CELL; MONOTHERAPY; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; SHORT COURSE THERAPY; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR REGRESSION; UPREGULATION;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; PILOT PROJECTS; RECEPTOR, ERBB-2; RECEPTORS, IGG;

EID: 37549011436     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2068     Document Type: Article

References (37)

1. Burstein HJ, Winer EP. HER2 or not HER2: that is the question. J Clin Oncol 2005;23:3656-9.
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
4. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
5. Mohsin SK, Weiss HL, Gutierrez MC, et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005;23:2460-8.
6. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3:269-80.
7. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007; 18:977-84.
8. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6:443-6.
9. Fleming GF, Meropol NJ, Rosner GL, et al. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res 2002;8: 3718-27.
10. Repka T, Chiorean EG, Gay J, et al. Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin Cancer Res 2003;9:2440-6.
11. Parihar R, Nadella P, Lewis A, et al. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res 2004; 10:5027-37.
12. Gennari R, Menard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004;10:5650-5.
13. Arnould L, Gelly M, Penault-Llorca F, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006;94:259-67.
14. Menard S, Pupa SM, Campiglio M, et al. Apoptosis induction by trastuzumab: possible role of the core biopsy intervention. J Clin Oncol 2005;23:7238-40.
15. Preithner S, Elm S, Lippold S, et al. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol 2006;43:1183-93.
16. Carson WE, Parihar R, Lindemann MJ, et al. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 2001;31:3016-25.
17. + T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen). J Exp Med 1985;162:2089-106.
18. Lefebvre ML, Krause SW, Salcedo M, Nardin A. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J Immunother 2006;29: 388-97.
19. Stockmeyer B, Beyer T, Neuhuber W, et al. Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells. J Immunol 2003;171:5124-9.
20. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc γRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc γRIIIa, independently of the Fc γRIIIa-48L/R/H phenotype. Blood 1997;90:1109-14.
21. Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64:4664-9.
22. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7.
23. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002;99:754-8.
24. Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 2005; 23:474-81.
25. Farag SS, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC. Fc γ RIIIa and Fc γ RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 2004;103:1472-4.
26. Lin TS, Flinn IW, Modali R, et al. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood 2005;105:289-91.
27. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
28. Fagnoni FF, Oliviero B, Giorgiani G, et al. Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after allogeneic myeloablative hematopoietic stem cell transplantation. Blood 2004;104:281-9.
29. Kono K, Ressing ME, Brandt RM, et al. Decreased expression of signal-transducing ζ chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 1996;2:1825-8.
30. Bottcher S, Ritgen M, Bruggemann M, et al. Flow cytometric assay for determination of FcγRIIIA-158 V/F polymorphism. J Immunol Methods 2005;306:128-36.
31. Mikulski SM, Billing R, Terasaki PI. Inhibition of effector cell function in human antibody-dependent cellular cytotoxicity by sera from cancer patients. J Natl Cancer Inst 1977;58:1485-7.
32. Iida S, Misaka H, Inoue M, et al. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcγRIIIa. Clin Cancer Res 2006;12:2879-87.
33. Huizinga TW, de Haas M, van Oers MH, et al. The plasma concentration of soluble Fc-γ RIII is related to production of neutrophils. Br J Haematol 1994;87: 459-63.
34. Mazouni C, Hall A, Broglio K, et al. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer 2007;109:496-501.
35. Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods 2005;304:88-99.
36. Roda JM, Parihar R, Magro C, Nuovo GJ, Tridandapani S, Carson WE 3rd. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res 2006;66:517-26.
37. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/neu-positive metastatic breast cancer [abstract 4188]. 2007 AACRA nnual Meeting, April 14-18, 2007, Los Angeles, CA.